Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce entering an advanced stage in a joint trial in partnership with the Israel Institute for Biological Research (the "IIBR"). This study explores,…
The drug MesenCure reduced life-threatening cytokine release syndrome, which occurred as a result of immunotherapy for the treatment of cancer Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that Jackson…
Collaboration with one of Europe's leading research centers in personalized medicine aims to accelerate clinical development. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is delighted to announce the signing of a strategic cooperation…
Orthopedic Surgeons to Showcase Successful Treatment of Bone Deficiencies with BonoFill, a Live Human Bone Graft by Bonus Biogroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus Biogroup is pleased to announce that orthopedic surgeons…
The Israel Ministry of Health certified the facility and process for producing the investigational drug MesenCure to comply with Good Manufacturing Practices (GMP) according to the recommendations of the World Health Organization. Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered…